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Purpose of the study
Aging may have an effect on the pharmacokinetics (PK) of
antiretroviral drugs and hence contribute to differences in
efficacy and toxicity. We evaluated the impact of age on
the pharmacokinetics of boosted atazanavir in a Thai HIV-
1 infected population.
Methods
HIV-infected adults (viral load < 50) on atazanavir/riton-
avir 300/100 mg once-daily plus two NRTIs for at least 2
weeks were enrolled. Two 24-hour intensive PK were stud-
ied at baseline and 14 days after switching to atazanavir/
ritonavir 200/100 mg once-daily regimen plus two NRTIs.
Atazanavir plasma concentrations were calculated using
non-compartmental methods. A repeated measures GEE/
random effect model was used to compare the two dose
levels. Comparison between the different subgroups were
made using the Mann-Whitney U model.
Summary of results
There were 22 patients (11 males, 11 age> 42 yrs, seven
tenofovir use, median BW = 59 kg). Females had a signif-
icantly lower BMI and BW; other demographics were sim-
ilar. Women had greater atazanavir exposure compared to
men with a median AUC of 70.54 vs. 59.76 mg/L.h (p =
0.039); Ctrough of 1.56 vs. 0.89 mg/L (p = 0.039) and
slower clearance 4.25 vs. 5.02 L/hr (p = 0.029). The age
group >42 years did not differ in terms of demographics
compared to the lower age group (<42 years). The ata-
zanavir levels were significantly higher in the older age
group with a slower clearance compared to the younger
for atazanavir/ritonavir 300/100 only [median AUC
71.23 vs. 53.1 mg/L.h (p = 0.014); Cmax 8.45 vs. 5.48 mg/
L (p = 0.001); Ctrough1.07 vs. 0.78 mg/L (p = 0.012) and
clearance 4.21 vs. 5.65 L/hr (p = 0.014)]; 91% of older
group compared to 36% of younger (p = 0.009) had ata-
zanavir Ctrough above 0.85 mg/L. There was an associa-
tion between lower weight and higher AUC0–24 as well.
In multivariate analysis, weight and gender were no
longer significant predictors of AUC0–24. Only age was
highly significantly associated with AUC0–24 (p =<
0.001), Cmax (p =< 0.001), Ctrough (p = 0.012), and
clearance (p = 0.002). However, body weight was associ-
ated with Cmax (p = 0.006). There was no significant rela-
tionship between half-life and gender, weight, age,
whether the patient was using TDF or the AUC0–24 of
RTV.
Conclusion
Older patients appear to have different PK profiles for ata-
zanavir in our population. Large trials are warranted to
confirm this result.
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